Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

NCT04375527 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped poor enrollment

Conditions

Clinical Stage III Cutaneous Melanoma AJCC V8
Clinical Stage IV Cutaneous Melanoma AJCC V8
Locally Advanced Cutaneous Melanoma
Metastatic Cutaneous Melanoma
Pathologic Stage III Cutaneous Melanoma AJCC V8
Pathologic Stage IIIA Cutaneous Melanoma AJCC V8
Pathologic Stage IIIB Cutaneous Melanoma AJCC V8
Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
Pathologic Stage IIID Cutaneous Melanoma AJCC V8
Pathologic Stage IV Cutaneous Melanoma AJCC V8
Unresectable Cutaneous Melanoma

Interventions

DRUG: Binimetinib
BIOLOGICAL: Nivolumab
OTHER: Questionnaire Administration

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]